

ABSTRACT

Drug Utilization Study of Chemotherapy in Patient with Diffuse Large B Cell Lymphoma (DLBCL) (Study at Dr. Soetomo General Hospital Surabaya)

Dirani

Non-Hodgkin Lymphoma (NHL) is a large group of primary malignancy of solid lymphoid tissue. Diffuse Large B Cell Lymphoma (DLBCL) is the most common subtype of NHL. It has an aggressive natural history but responds well to chemotherapy. The objective of this study was to review the use of chemotherapy, identify the side effects and to acknowledge the response of chemotherapy in NHL patients at Dr. Soetomo General Hospital. It was a retrospective observational study using secondary data obtained from patient's medical records from January 2016 to December 2018. Results revealed that of the 43 patients who met the inclusion criteria, male (74%) was the most common gender in this study with 54% patients was in the 51-60 years old group of age. Most of the patients had weight loss and fever (72%) as chief complaint with neck (53%) as the most common site of tumor. About 44% patients had stage III and hypertension (5%) was the most comorbid disease found. R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) regimen (53%) was the most chemotherapy regimen used in this study. Results of the chemotherapy were good response in 65% and no response in 35%. The most common side effects in this study were myelosuppression including anemia (25%), leukopenia (8%) and thrombocytopenia (1%).

Keywords: drug utilization study, non-Hodgkin lymphoma, diffuse large b cell lymphoma, chemotherapy.